Rezolute Says FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism Treatment
MT newswire2026/10/05 12:0408:04 AM EDT, 10/05/2026 (MT Newswires) -- Rezolute (RZLT) said Monday that the US Food and Drug Administration has recommended a meeting before its submission of a biologics license application for its drug ersodetug as a potential treatment for hypoglycemia due to congenital hyperinsulinism. The proposed meeting follows a preliminary review of data from a phase 3 study which did not meet the primary endpoint because the reductions in hypoglycemia events by finger-stick self-monitored blood glucose were not statistically significant compared to placebo, the company said. A key secondary endpoint of time in hypoglycemia was not met, although "consistent and clinically relevant improvements" in hypoglycemia were observed, the company said. The FDA did not opine on the approvability of ersodetug and noted any such determination would only be made as part of an in-depth evaluation of the supporting data during a formal BLA review, as is customary during a BLA process. Shares of the company were up 7.5% in recent premarket trading.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Crypto prices
More
